ASTELLAS, ASP015K- JNJ as Global Partner Lifts Commercial Attractiveness!

Date: 2015-07

“Astellas announced to partner with Janssen pharma to develop and commercialize ASP015K (PhIIb, JAK inhibitor, RA, psoriasis) for WW territories excluding Japan. Though Astellas has enjoyed a strong hold in immunosuppressant market with Prograf franchise, ASP015K’s target market (RA, psoriasis) is distinct and offers ~no advantages to be leveraged from – at least on marketing front!
In this report we have analyzed rational for Astellas to partner with Janssen and its strong position in immunology market, potential of ASP015K and increasing competition in RA and psoriasis oral drugs market.”


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample